The measurement of serum free T4 (FT4) by analogue methods has been severely criticised because the T4 analogue binds to albumin. Amersham have recently introduced a method utilising horseradish peroxidase-labelled-T4 (HRP-T4) designed to overcome this problem and have incorporated it into the Amerlite enhanced luminescence immunoassay system. We have critically evaluated this method for its analytical and clinical validity.
SUMMARY. The measurement of serum free T4 (FT4) by analogue methods has been severely criticised because the T4 analogue binds to albumin. Amersham have recently introduced a method utilising horseradish peroxidase-labelled-T4 (HRP-T4) designed to overcome this problem and have incorporated it into the Amerlite enhanced luminescence immunoassay system. We have critically evaluated this method for its analytical and clinical validity.
Experiments in which anti-albumin was added to normal serum suggested that the HRP-T4 label did not bind to endogenous albumin while the addition of albumin caused no significant change in FT4 concentration. Adding oleic acid up to 5 mmoljL to simulate increased non-esterified fatty acid concentration did not increase the apparent FT4.
Serum sampled from subjects independently allocated to clinical groups were compared with an euthyroid group. The untreated hyperthyroid group values were distinctly elevated while the untreated hypothyroid group were appropriately low. Oestrogen therapy, low TBG, familial dysalbuminaemic hyperthyroxinaemia and non-thyroidal illness groups all reflected their euthyroid status, as did pregnancy samples which also showed a tendency to lower values in late pregnancy, consistent with previous observations.
In conclusion, the Amerlite FT4 method appears to overcome some of the problems associated with analogue methods. A small survey showed it to be diagnostically valid in a wide variety of clinical states.
The measurement of serum free T4 (FT4) concentration, which has long been advocated as a useful test of thyroid function, became more practical as a routine procedure with the development of the antibody-coated tube method! followed by the labelled T4 analogue technique.' It was claimed that the T4 analogue did not compete with any of the bound T4 moieties for T4 antiserum. However, serious objections to this claim were raised both on practical! and theoretical" grounds. The binding of the analogue to serum albumin in particular, caused major inherent problems in the analogue kits.
Recently Amersham International pic (Aylesbury, UK) have released a new method for FT4 in association with the Amerlite immunoassay system. With the problems associated with the analogue methods in view, we have assessed the Amerlite FT4 for its methodological soundness and diagnostic performance.
Materials and methods

ANALYTICAL PROCEDURE
The FT4 method is performed on the Amerlite assay system which uses enhanced luminescence incorporating micro titre well technology with automatic washing, dose response assessment and data reduction. The Amerlite FT4 kit methodology is similar in concept to the analogue-type methods. In the analogue methods, a radioactively labelled analogue of T4 is used which is designed to bind to anti-T4 antibodies with an affinity equal to T4 but not to bind to the serum binding proteins. By contrast, the Amerlite FT4 system uses horseradish peroxidase (HRP)-eonjugated T4 in place of an analogue. The HRP is said to prevent the conjugated T4 from attaching to the serum binding proteins without interfering with the binding of the antibody to the T4 attached to the HRP. The HRP conjugated T4 (HRP-T4) and endogenous FT4 compete for anti-T4 antibody binding sites while protein bound T4 is denied entry to this competition thereby providing the basis for a FT4 assay. The anti-T4 antibody is bound by a second (donkey anti-sheep) antibody which is covalently attached to the wall of the incubation well. Following washing of the antibody-antibody complex, signal reagent is added and the signal is read in the Amerlite detector. A dose response curve is constructed and unknowns read from this curve.
EVALUATION OF FREE T4 METHODOLOGY
Effect of dilution
This was studied by the serial dilution of normal serum up to 1 in 32 in 0·01 mol/L phosphatebuffered saline pH 7-4 (Table 1 ) and measuring FT4 in the diluted samples.
Effect of additional albumin
This was studied by adding human serum albumin (Commonwealth Serum Laboratories, Melbourne, Australia) to two samples of normal human serum to a concentration of 75 giL of albumin. Each spiked sample was diluted stepwise with the original serum to give albumin concentrations ranging from 41 to 75 giL (Table  2 ) and FT4 was measured in each.
Binding of H RP-T4 to albumin
The ability of either endogenous human albumin or bovine serum albumin present in the kit, to bind the HRP-T4 label was assessed by adding sheep anti-human albumin (Silenus, Melbourne, Australia) or sheep anti-bovine albumin (Nordic Immunology Laboratories b.v. Tilburg, The Netherlands) to the assay system. The antialbumin antisera were serially diluted in normal human serum and the resulting mixtures were assayed in the presence and absence of the kit anti-T4 antibody.
Effect of non-esterified fatty acids (NEFA)
The effect ofNEFA on apparent FT4 concentration measured on the Amerlite system was assessed in a normal serum enriched with various concentrations of up to 10 rnmol/L as oleic acid (Fig. 2 ).
CLINICAL STUDIES
FT4 was measured in selected healthy individuals and in various groups of patients to assess the diagnostic performance of the Amerlite FT4 kit. The clinical groups studied were: healthy euthyroid individuals on no drugs (n=31); healthy euthyroid individuals taking oral contraceptives (n = 13); untreated hyperthyroid patients (n = 20); untreated hypothyroid patients (n = 20); healthy euthyroid pregnant patients-l st trimester (n = 17), 2nd trimester (n = 30), 3rd trimester (n = 19); healthy euthyroid individuals with low TBG (n = 8); subjects with familial dysalbuminaemic hyperthyroxinaemia (FDH) (n = 6); patients with severe non-thyroidal illnesses (NT!) (n =17).
Venous blood was sampled at random times through the day, serum collected and samples stored at -30 aC until assay.
FT4 was also measured in some samples by equilibrium dialysis (ED).s Albumin was measured on a Synchron AS (Beckman Instruments, California, USA) analyser, NEFA were measured by gas chromatography' and both total T4 and T4-binding globulin (TBG) were measured by double antibody radioimmunoassay established in this laboratory. (TABLE 1) The apparent FT4 concentration fell to approximately 50% of the undiluted value at a dilution ratio of 1; 16.
Results
EFFECT OF DILUTION
EFFECT OF ALBUMIN (TABLE 2) An incremental increase in the apparent FT4 concentration was observed in serum specimens of incrementally increasing albumin concentrations.
BINDING OF HRP-T4 TO ALBUMIN
In the absence of anti-T4 antibody no signal response was generated at any concentration of FIG2. The effectsof adding increasingamounts of oleic acid on the FT4 concentration as measured in the Amerlite FT4 system. The oleic acid value refers to the amount added to the serum (which contained 0·23 mmol/L of endogenous oleic acid).
CLINICAL STUDIES (FIG. 3) Amerlite FT4 values in the group of hyperthyroid patients were well differentiated from those of the euthyroid group. There was a small overlap in the results of the hypothyroid and euthyroid groups.
In pregnancy, values (pmol/L) of FT4 were 16·6± 3·4 for Amerlite (16,2 ± 2·1 for ED) in first trimester, 12·2± 1·9 for Amerlite (l2·0±2·4 for ED) in second trimester and 9·4±2·9 (1l·0±2·4 for ED) in the third trimester. FT4 results from all other groups fell within the euthyroid range. The outlier in the FDH group was found to have a total NEFA concentration of 3·7 mmol/L, Results for FT4 using ED in severe NT! were also normal (14·9±2·4 pmol/L).
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. Human serum albumin was added to normal serum and the resulting sample was diluted in normal human serum.
anti-human albumin antibody or anti-bovine albumin antibody (Anti-human albumin antibody being shown in Fig. I) . With anti-T4 antibody present the signal response increased as the anti-albumin concentration decreased.
EFFECTS OF NEFA
No effect on apparent FT4 concentration was detected with the addition ofless than 5·5 rnmol/L oleic acid; above this a step-wise increase occurred (Fig. 2) . FT4, when measured by ED, responded similarly, although somewhat more sensitively to added oleic acid. Unenriched serum measured 16·2 pmol/L ofFT4 by ED and follow- 
Discussion
The Amerlite FT4 assay is somewhat similar to the analogue FT4 assays in concept except that the HRP-T4 label is prevented from occupying serum T4-binding sites, presumably by steric hindrance, rather than by a chemical modification.
It can be shown in both theory and practice that free T4 concentration is independent of dilution up to at least I: 150'? This means that a dilution study, in which the free T4 concentration should remain constant over a range of dilution factors, can be used as a validation test for a free T4 assay, The fall in free T4 to approximately 50% of its original concentration at a dilution of 1: 16 (representing a dilution of 1: 144 when 3% · · · · · · · · .. ... ------------------------------....----... ----_. ------------------------------------ sample to reagent volume is considered) is not commensurate with the expected fall in total T4. Total T4 would be expected to fall to 6% of the original value at this dilution. Although not independent of dilution, the limitation of the observed fall to 50% of the original value, suggests that the assay partly follows the laws of mass action. Probably the manufacturer's addition of albumin to the assay system accounts for all or most of the decrease because, with progressive dilution, the amount of albumin relative to T4 increases due to the albumin present in the reagents. The increasing albumin may sequester increasing amounts of T4. Amersham International state in correspondence that their dilution experiments had been done only with added albumin which makes the validation of this aspect of the assay suspect as the effect of the relative changes in albumin concentration cannot be quantitated.
· · · · ·
Increasing the amount ofalbumin in serum was associated with an increase in the apparent FT4 concentration. However this can be explained by the small change in TBG concentration resulting from dilution of the serum with albumin ( Table  2) . Dilution did not result in a change in total T4 concentration as the albumin solution used contained 90 nmol/L of T4.
The addition of anti-albumin indicated neither human nor bovine albumin bound the HRP-T4 complex. In the presence ofanti-T4 antibody and the highest concentrations of anti-albumin no signal response was seen. As the concentration of anti-albumin decreased the signal response increased. This increase in response occurs as the anti-sheep antibodies on the well wall are no longer occupied by anti-albumin and become occupied by anti-T4 which binds the HRP-T4 complex. Without anti-T4 no signal response is seen at any concentration of anti-albumin. These results indicate that the anti-albumin is being bound by the antibodies on the well wall and that HRP-T4 is not binding to albumin.
Oleic acid additions caused an increase in FT4 concentration only when the oleic acid concentration reached approximately 5 mmol/L, Oleic acid was chosen because it is the most abundant NEFA present in serum. This concentration of NEFA is well outside those found in pathophysiological situations. Observations in this laboratory indicate that at -20°C no rise in NEFA is seen in 6 months. At 4°C a rise in NEFA to approximately 2 rnmol/L is seen in 6 weeks. With this in mind, the wisdom of adding albumin to the reagents, ostensibly to negate the effects of increased NEFA due to storage must be questioned. Physiological increases in NEFA, while usually not of great magnitude, may cause a rise in the free fraction ofT4 and adding albumin will mask this real increase. The albumin addition may also mask.an increase in free fraction ofT4 in patients receiving chronic therapy with drugs capable of displacing T4 from albumin.
The primary purpose of this study was to assess the validity of the Amerlite FT4 assay system rather than to perform a comprehensive clinical analysis. Nevertheless, from the preliminary studies of the clinical groups, it may be concluded that the assay is clinically useful. It differentiates FT4 values of hyperthyroid patients from those of healthy individuals which ranged from 7·2 to 20·1 pmol/L, The observations were made prior to the manufacturer's recalibration of the assay. The current reference interval for normal individuals with this assay in this laboratory is 10-25 pmol/L, The small overlap between hypothyroid patients and healthy individuals is expected as is the small progressive decrease in FT4 occurring in pregnancy. It corrects well for disturbed binding states including the extreme example of FDH. The normal results of Amerlite FT4 in NT! patients also validates the assay as FT4 by ED is also normal in contrast to the low values found in the many other assays which are profoundly susceptible to interference by NEFA in the presence of decreased serum binding of T4.
We conclude that the Amerlite free T4 system is unaffected by increased albumin concentration, and that the HRP-T4 label does not bind to albumin. The results in normal individuals and in patients indicate the assay is clinically mean-Amerlite free T4 521
ingful. Increasing the oleic acid content to concentrations greater than 5 mrnol/L caused an artefactually raised FT4 despite the addition of albumin to the reagents. Dilution studies indicated the assay system, while not ideal, obeyed the laws of mass action, at least at small dilution ratios. The Amerlite free T4 assay system seems to have overcome the major problems associated with the analogue type assays.
